With a rich culture of discovery and deep expertise in oncology, ImClone Systems is dedicated to advancing oncology care by developing and commercializing targeted biologic treatments. Founded in 1984, the company has built a pipeline of product candidates that address specific genetic mechanisms involved in cancer growth and development. In addition to its blockbuster product ERBITUX®, ImClone has several investigational monoclonal antibodies in various stages of clinical development. Through its acquisition by Eli Lilly and Company in 2008, ImClone is leveraging Lilly's global capabilities to accelerate its antibody pipeline development. With a focus on mid- to late-stage clinical development, ImClone aims to target virtually all major solid tumor types. The company also plans to advance additional targets from its research programs into clinical development in the future. ImClone's manufacturing facilities in New Jersey provide it with one of the largest biologic manufacturing capacities globally, supporting its research and clinical development operations.